Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact
Int J Tuberc Lung Dis
.
2012 May;16(5):701; author reply 702.
doi: 10.5588/ijtld.12.0131.
Authors
Stephen D Lawn
,
Andrew D Kerkhoff
,
Robin Wood
PMID:
22507934
DOI:
10.5588/ijtld.12.0131
No abstract available
Publication types
Letter
Comment
MeSH terms
Antitubercular Agents / pharmacology*
Humans
Nucleic Acid Amplification Techniques / methods*
Rifampin / pharmacology*
Tuberculosis / diagnosis*
Substances
Antitubercular Agents
Rifampin